These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7059976)

  • 21. Studies on tumor-host relationship. V. Effect of myo-inositol on tumor cell growth in vivo and on the resistant activity of the host.
    Tanino T; Narumi K; Tsumita T
    Jpn J Exp Med; 1972 Dec; 42(6):575-82. PubMed ID: 4540908
    [No Abstract]   [Full Text] [Related]  

  • 22. Interaction in culture between mouse ascites mammary carcinoma (MM2) cells and lymphoid cells of isologous mice.
    Katsuta H; Ashikawa K; Takaoka T
    Jpn J Exp Med; 1975 Jun; 45(3):223-9. PubMed ID: 1177362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impairment of several forms of lymphocyte and hematopoietic stem cell interaction during tumor growth].
    Khaitov RM; Gambarov SS; Petrov RV; Norimov ASh
    Vopr Onkol; 1976; 22(3):49-54. PubMed ID: 945641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of tumor growth and cell-mediated immune responses of mice bearing mammary tumors following surgical procedures.
    Lopez DM; Sigel MM
    J Reticuloendothel Soc; 1975 Nov; 18(5):305-12. PubMed ID: 1206665
    [No Abstract]   [Full Text] [Related]  

  • 25. Cycling of immune responses to a syngeneic murine mammary adenocarcinoma.
    Huber SA; Bigi G; Lucas ZJ
    Cancer Res; 1980 Oct; 40(10):3484-90. PubMed ID: 6449282
    [No Abstract]   [Full Text] [Related]  

  • 26. Mammary tumor immune enhancement in mice by local hyperemia.
    Vaage J
    Cancer Res; 1986 Jan; 46(1):386-9. PubMed ID: 3940204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inherent changes in the in vivo growth characteristics of C3H/He mammary carcinomas.
    Vaage J
    Cancer Res; 1980 Oct; 40(10):3495-3501. PubMed ID: 7438036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of autosensibilization of lymphoid cells in genesis of antitumor resistance.
    Malygin AM; Fel VJ
    Neoplasma; 1979; 26(4):429-37. PubMed ID: 522915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced immune reactivity to hepatoma 22a cells in MTV-infected compared with MTV-free C3H mice.
    Lavrovsky VA; Viksler VK
    Immunology; 1981 Dec; 44(4):671-6. PubMed ID: 6274791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
    Ben-Hur H; Kossoy G; Zandbank J; Zusman I
    Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A; Nowicky JW
    Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of shared nonviral tumor-associated transplantation-type antigens among C3H/He mammary carcinomas.
    Vaage J
    Cancer Res; 1984 May; 44(5):1876-9. PubMed ID: 6201265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between tumor growth characteristics and preferential sites of growth.
    Vaage J
    J Natl Cancer Inst; 1984 May; 72(5):1199-203. PubMed ID: 6585595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
    Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM
    Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor.
    Miller BE; Miller FR; Leith J; Heppner GH
    Cancer Res; 1980 Nov; 40(11):3977-81. PubMed ID: 7471048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of cell proliferation rather than of cell lysis as a measure of immune reactivity in embryo-antigen-challenged mice.
    Gorczynski RM; MacRae S
    Br J Cancer; 1981 Jan; 43(1):19-31. PubMed ID: 7459234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic variance among cells isolated from spontaneous mouse mammary tumors in primary suspension culture.
    Soule HD; Maloney T; McGrath CM
    Cancer Res; 1981 Mar; 41(3):1154-64. PubMed ID: 7459857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.